News

The Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic discussed the complexities with identifying viable biomarkers for Parkinson disease, as well as interventions geared toward specific regions of the brain. [WATCH TIME: 4 minutes]

Treatment with remote ischemic conditioning performed twice daily for 2 weeks as an adjunct to guideline-based treatment resulted in higher odds of modified Rankin Scale scores between 0 and 1, and 0 and 2.

In a multiday ascending dose trial, pharmacokinetic analysis indicated a direct linear relationship between drug dosing concentration and blood plasma levels for each of the 5 days of dosing.

The publication’s findings were consistent with previous scientific literature suggestive that Alzheimer disease is a multifactorial disease, where several pathways interlink and cause cognitive impairments.

The molecular biologist at the Cleveland Clinic Lerner Research Institute provided insight on the lingering questions about GFAP and sTREM2 astrocytes, and their immunologic correlations with Alzheimer disease and related dementias. [WATCH TIME: 4 minutes]

The Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic discussed a new virtual reality tool that quantifies prodromal changes in activities of daily living for Parkinson disease, without incurring issues of sensory fatigue.

The findings suggests that existing migraine preventative medications are commonly prescribed in idiopathic intracranial hypertension, the most common of which were acetazolamide and topiramate.

Magnetoencephalography provides an opportunity for physicians to capture a more dynamic view of brain function over time and space that may offer an advantage to clinical care.

The associate director of the Sleep Center at Children’s Hospital of Philadelphia discussed the detrimental effects poor sleep can have on children, both neurologically and on quality of life. [WATCH TIME: 4 minutes]

After adjusting for stroke severity, prestroke physical activity still accounted for a 52% lowered risk for long-term morality following intracerebral hemorrhage and 48% after ischemic stroke.

Although the prevalence of epilepsy among veterans was similar to what has been reported in the literature, those with DRE had a mortality rate higher than the US general population and other veterans.

CXCL2 and CXCL12, known to induce B-cell proliferation and differentiation, were significantly higher in those with acute and remitted cases of NMOSD compared with controls.

The Edward F. and Barbara A. Bell Endowed Chair at the Cleveland Clinic detailed how a new virtual reality tool elucidates prodromal symptoms from patients with Parkinson disease. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Patients who received tirofiban did not differ from placebo in terms of 90-day outcomes, and they showed an increased incidence of symptomatic intracranial hemorrhage.

The director of the Women’s Alzheimer’s Movement Preventer Center at Cleveland Clinic provided perspective on the possibility of gender-specific therapies to overcome disparities in Alzheimer disease. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

More than 60% of patients with early-onset dementia with Lewy bodies had a least 3 of the 5 identified factors at first clinic visit, compared with fewer than 20% of those with early-onset Alzheimer disease.

The long-term consequences of untreated—and prevalent—sleep disorders in children and adolescents point to a need for a focus on this field of care.

Neurology News Network for the week ending August 20, 2022. [WATCH TIME: 4 minutes]

The chair of the American Migraine Foundation spoke about the insight gleaned from a recent survey the foundation conducted assessing links between mental health and migraine care. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 19, 2022.

The phase 3 trial will include a double-blind period evaluating the safety and efficacy of cannabidiol (Epidiolex) for 14 weeks, followed by an open-label extension lasting 54 weeks.

Following positive phase 3 findings, a second study featuring more than 300 patients will aim to confirm PXT3003’s effect in patients with Charcot-Marie-Tooth disease type 1a.

Mendelian randomization analyses identified a significant association between genetically determined chronic kidney disease and intracerebral hemorrhage risk, supporting a causal association between the 2 conditions.

The investigational therapy is a twice-daily injectable identical formulation of the protein ghrelin, being assessed in a 2-part trial including individuals who are highly symptomatic within 28 days of brain injury.

The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed research on the use of GFAP and sTREM2 in discerning dementia with Lewy bodies from Alzheimer disease. [WATCH TIME: 4 minutes]

Joseph E. Sullivan, MD; Kelly Knupp, MD; Mary Anne Meskis; and Tracy Dixon-Salazar, PhD, share insight into the patient and provider journey of LGS and Dravet syndrome, from diagnosis through treatment.

The postdoctoral researcher at King’s College London provided background on why gene therapies have not seen as much success in treating ALS, and the need for additional validation of genetic mutations. [WATCH TIME: 3 minutes]

The correction in Muscle & Nerve resulted in a statistically significant treatment difference of more than 2 points for average change from baseline in ALSFRS-R in the prespecified efficacy subgroup of with a baseline score of at least 35.